贞芪六君抑癌汤配合mFOLFOX6联合贝伐珠单抗治疗晚期转移性结直肠癌临床疗效分析

Clinical Efficacy Analysis of Zhenqi Liujun Anti-cancer Decoction Combined with mFOLFOX6 and Bevacizumab in Treatment of Advanced Metastatic Colorectal Cancer

目的观察贞芪六君抑癌汤配合mFOLFOX6方案联合贝伐珠单抗治疗晚期转移性结直肠癌的临床疗效。方法回顾性分析2018年1月~2020年9月晚期转移性结直肠癌脾虚证患者76例,将研究对象分为试验组39例和对照组37例,两组均采用mFOLFOX6方案联合贝伐珠单抗治疗,共12周期;其中试验组配合贞芪六君抑癌汤治疗,化疗前1天开始服用,每日一剂,连服2周。比较两组患者治疗后的客观反应率(objective responserate,ORR)、疾病控制率(disease controlrate,DCR)、不良反应及生活质量。结果试验组ORR为58.97%,DCR为84.62%;对照组ORR为45.95%,DCR为62.16%;两组ORR比较差异无统计学意义,试验组DCR优于对照组(P<0.05)。安全性比较,试验组Ⅲ~Ⅳ级胃肠道反应和骨髓抑制发生情况少于对照组(P<0.05),低蛋白血症发生少于对照组(P<0.05)。生活质量评价,试验组KPS评分优于对照组(P<0.05)。结论贞芪六君抑癌汤配合mFOLFOX6方案联合贝伐珠单抗。可提高晚期转移性结直肠癌患者的DCR,还可减轻化疗毒副反应和提高生活质量。

Objective To observe the clinical efficacy of Zhenqi Liujun Anti-cancer Decoction(ZLAD)combined with mFOLFOX6 regimen and bevacizumab in the treatment of advanced metastatic colorectal cancer.Methods A total of 76 patients with advanced metastatic colorectal cancer differentiated as spleen deficiency syndrome and admitted from January 2018 to September 2020 were retrospectively analyzed.The patients were divided into experimental group(39 cases)and control group(37cases).Both groups were treated with mFOLFOX6 regimen combined with bevacizumab for 12 cycles,and the patients in experimental group were also given oral use of ZLAD for continuous 2 weeks(one dose per day,one day before chemotherapy).The objective response rate(ORR),disease control rate(DCR),adverse reaction,and quality of life in the two groups were compared.Results The ORR and DCR in the experimental group were 58.97%and 84.62%respectively,and in the control group were 45.95%and 62.16%respectively.There was no significant difference in ORR between the two groups,and DCR in the experimental group was higher than that in control group(P<0.05).In respect of adverse reaction,the incidences of the gastrointestinal toxicity gradeⅢ~Ⅳ,bone marrow toxicity,and hypoproteinemia in the experimental group were lower than those in the control group(P<0.05).In respect of the quality of life,KPS scores in the experimental group were higher than those in the control group(P<0.05).Conclusion ZLAD combined with mFOLFOX6 regimen and bevacizumab can improve the DCR of advanced metastatic colorectal cancer,reduce toxic and side effects of chemotherapy and improve the quality of life,which is worthy of further research.